Summit Chair: JR Dobbins, Eli Lilly and Company

Accelerating the Development of Adeno-Associated Viral Vector Gene Therapies: Innovations in Chemistry, Manufacturing, and Control

Gene therapy using adeno-associated viral (AAV) vectors has emerged as a transformative approach for treating a variety of genetic conditions. Many of these novel therapies are being developed to treat rare diseases with unmet medical needs, necessitating the rapid advancement through development and commercialization. The inherent complexity of AAV vectors has historically presented challenges in advancing the chemistry, manufacturing, and control (CMC) aspects commensurate with the pace of clinical development.

This virtual summit will bring individuals from academia, industry, and health authorities together to discuss innovative CMC approaches. Attendees will gain insights into CMC strategies, challenges, and opportunities to accelerate the development and commercialization of AAV therapies. The summit will be comprised of two sessions that focus on development of the process and product control strategy along with commercialization topics such as technology transfer and process performance qualification strategies. Each session will consist of multiple presentations and a panel discussion providing attendees the opportunity to learn from and interact with experts in the field.

By attending this summit, you will connect virtually with a relevant global network and gain tangible knowledge to help you more rapidly and robustly advance these transformative AAV vector therapies to patients who need them.

JR Dobbins

Appearances